Table 3 First-line ARV regimen prices comparisons, 2008
| Â | Indian generic median price (25th, 75th) | Non-Indian generic median price (25th, 75th) | Innovator actual median price (25th, 75th) | Innovator survey price** Cat 1, Cat 2 |
|---|---|---|---|---|
First-line regimens from 2003 WHO guidelines: | Â | Â | Â | Â |
3TC/NVP/d4T30 | 74 (63, 88) | 154* (137, 712) | N/A | 331, 570 |
EFV+3TC/d4T30 | 131 (126, 193) | 229* (196, 656) | N/A | 349, 789 |
3TC/NVP/ZDV | 120 (118, 123) | 142 (142, 142) | 519* (496, 991) | 444, 663 |
EFV+3TC/ZDV | 183 (177, 260) | 326 (254, 348) | 491 (475, 801) | 434, 854 |
New first-line regimens from 2009 WHO guidelines: | Â | Â | Â | Â |
3TC+NVP+TDF | 246 (230, 273) | 340 (321, 767) | 575 (519, 1254) | 490, 867 |
EFV+3TC+TDF | 298 (283, 369) | 415 (381, 711) | 546 (498, 1064) | 508, 1086 |
FTC/TDF+NVP | 257 (247, 301) | 387 (386, 537) | 641 (569, 1116) | 538, 986 |
EFV+FTC/TDF | 309 (300, 397) | 461 (446, 480) | 612 (548, 926) | 556, 1205 |